<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004980</url>
  </required_header>
  <id_info>
    <org_study_id>R21MH063326</org_study_id>
    <secondary_id>R21MH063326</secondary_id>
    <secondary_id>YALESM-9281</secondary_id>
    <secondary_id>199/14809</secondary_id>
    <secondary_id>A5-ETPD</secondary_id>
    <nct_id>NCT00004980</nct_id>
  </id_info>
  <brief_title>Repetitive Transcranial Magnetic Stimulation for &quot;Voices&quot;</brief_title>
  <official_title>Repetitive Transcranial Magnetic Stimulation of Speech Processing Brain Areas in Schizophrenic Patients Who Hear &quot;Voices&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Determine the effect of repetitive transcranial magnetic stimulation on treatment
      refractory auditory hallucinations of patients with schizophrenia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind study. Patients are randomized to one of
      two treatment arms.

      Group I: Patients receive 9 sessions of active transcranial magnetic stimulation (rTMS) which
      consists of 8 minutes of rTMS during session 1, 12 minutes duration during session 2, and 16
      minutes duration during sessions 3-9. The total duration of stimulation is 132 minutes. Each
      session was given on a separate day and in general each session occurred on consecutive days
      with the exception of weekends.

      Group II: Patients receive 9 sessions of sham stimulation, which consists of 8 minutes of
      sham stimulation during session 1, 12 minutes duration sham stimulation during session 2, and
      16 minutes duration sham stimulation during sessions 3-9. The total duration of sham
      stimulation is 132 minutes. Each session was given conducted on a separate day and in general
      each session occured on consecutive days with the exception of weekends.

      This study provided pilot data supplying the basis for our current study - NCT00308997 -- see
      our website for details
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">January 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hallucination Change Score (HCS) After 9 Active/Sham rTMS Sessions</measure>
    <time_frame>After the 9th active/sham rTMS session (up to 2 weeks or end of intervention)</time_frame>
    <description>Change in hallucination severity relative to baseline with scores ranging 1 in unit intervals to 20 anchored as follows: 0=hallucinations stopped, 10=no change, 20=hallucinations twice as severe as baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hallucination Frequency After 9 Active/Shame rTMS Sessions</measure>
    <time_frame>After the 9th active/sham rTMS session (up to 2 weeks or end of intervention)</time_frame>
    <description>Difference between baseline hallucination frequency and hallucintion frequency at last assessment. Assessed on the basis of a 0-9 scale, with higher scores being more severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Improvement (CGI) Scale After 9 Active/Shame rTMS Sessions</measure>
    <time_frame>After the 9th active/sham rTMS session (up to 2 weeks or end of intervention)</time_frame>
    <description>Scaled from 1-7 as follows: 1=dramatically improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worsened, 6=moderately worsened, 7=dramatically worsened</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder Status</measure>
    <time_frame>After the 9th active/sham rTMS session (up to 2 weeks or end of intervention)</time_frame>
    <description>Responder defined as a participant who attains an endpoint hallucination change score (HCS) of 5 or lower after 9 active/shame rTMS sessions.
Change in hallucination severity relative to baseline with scores ranging 1 in unit intervals to 20 anchored as follows: 0=hallucinations stopped, 10=no change, 20=hallucinations twice as severe as baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>active rTMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1-Hz rTMS delivered to left temporoparietal cortex at 90% motor threshold for 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sham stimulation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sham stimulation delivered 16 minutes per session given one session per day for nine consecutive days (with the exception of weekends)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive transcranial magnetic stimulation (rTMS)</intervention_name>
    <description>a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site</description>
    <arm_group_label>active rTMS</arm_group_label>
    <other_name>MATSTIM SUPER RAPID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>sham stimulation</intervention_name>
    <description>132 minutes of stimulation given at 80% motor threshold with coil tilted &quot;single wing&quot; 45 degrees away from scalp deliverd to TP3 site</description>
    <arm_group_label>sham stimulation</arm_group_label>
    <other_name>MAGSTIM SUPER RAPID</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        Inclusion criteria:

          -  Diagnosis of schizophrenia or schizoaffective disorder based on DSM-IV version of SCID

          -  Auditory hallucinations of spoken speech occurring at least 5 times per day where
             subject able to discern verbal content

          -  Right-handed

          -  At least 4 weeks on stable antipsychotic medication

        Exclusion criteria:

          -  history of seizure (unless due to drug withdrawal or medication that is no longer
             prescribed)

          -  history of epilepsy in first degree relatives

          -  estimated IQ less than 80

          -  unable to provide informed consent

          -  significant unstable medical condition

          -  current treatment with clozapine or bupropion

          -  cochlear implants or other metal in the head (surgical, etc.)

          -  history of cardiac arrhythmia

          -  cardiac pacemaker

          -  active drug or alcohol abuse within prior 6 weeks

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Hoffman</last_name>
    <role>Study Chair</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520-8099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://psychiatry.yale.edu/research/programs/clinical_people/rtms.aspx</url>
    <description>Click here for the Yale School of Medicine Web site describing current, on-going rTMS trial for auditory hallucinations</description>
  </link>
  <results_reference>
    <citation>Hoffman RE, Gueorguieva R, Hawkins KA, Varanko M, Boutros NN, Wu YT, Carroll K, Krystal JH. Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry. 2005 Jul 15;58(2):97-104.</citation>
    <PMID>15936729</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2000</study_first_submitted>
  <study_first_submitted_qc>March 10, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2000</study_first_posted>
  <results_first_submitted>November 25, 2008</results_first_submitted>
  <results_first_submitted_qc>June 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2012</results_first_posted>
  <last_update_submitted>August 5, 2013</last_update_submitted>
  <last_update_submitted_qc>August 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurologic and psychiatric disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Repetitive Transcanial Magnetic Stimulation</title>
          <description>Participants received active repetitive transcranial magnetic stimulation (rTMS)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received sham stimulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>memory difficulties</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Repetitive Transcanial Magnetic Stimulation</title>
          <description>Participants received active repetitive transcranial magnetic stimulation (rTMS)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received sham stimulation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="11.9"/>
                    <measurement group_id="B2" value="35.5" spread="9.5"/>
                    <measurement group_id="B3" value="35.3" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medication Resistance</title>
          <description>Number of participants who were medication resistant</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Medication Resistant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Medication Resistant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Auditory Hallucination Rate Scale (AHRS) score</title>
          <description>Sum of 7 variables: frequency of hallucinations, reality of hallucinations, loudness of hallucinations, number of acoustically distinct voices, length of hallucinations, attentional salience of hallucinations, level of distress induced by hallucinations; higher score connotes more severe hallucinations; lowest score is 4, highest score is 37</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="5.0"/>
                    <measurement group_id="B2" value="26.1" spread="5.7"/>
                    <measurement group_id="B3" value="25.6" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hallucination Change Score (HCS) After 9 Active/Sham rTMS Sessions</title>
        <description>Change in hallucination severity relative to baseline with scores ranging 1 in unit intervals to 20 anchored as follows: 0=hallucinations stopped, 10=no change, 20=hallucinations twice as severe as baseline</description>
        <time_frame>After the 9th active/sham rTMS session (up to 2 weeks or end of intervention)</time_frame>
        <population>Last Observation Carried Forward (LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Active Repetitive Transcanial Magnetic Stimulation</title>
            <description>Participants received active repetitive transcranial magnetic stimulation (rTMS)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received sham stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Hallucination Change Score (HCS) After 9 Active/Sham rTMS Sessions</title>
          <description>Change in hallucination severity relative to baseline with scores ranging 1 in unit intervals to 20 anchored as follows: 0=hallucinations stopped, 10=no change, 20=hallucinations twice as severe as baseline</description>
          <population>Last Observation Carried Forward (LOCF)</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.85" spread="2.85"/>
                    <measurement group_id="O2" value="8.61" spread="3.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.005</p_value>
            <p_value_desc>a priori threshold for statistical significance was .05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>degree of freedom = 48</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.76</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.514</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-4.65</ci_lower_limit>
            <ci_upper_limit>-.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hallucination Frequency After 9 Active/Shame rTMS Sessions</title>
        <description>Difference between baseline hallucination frequency and hallucintion frequency at last assessment. Assessed on the basis of a 0-9 scale, with higher scores being more severe.</description>
        <time_frame>After the 9th active/sham rTMS session (up to 2 weeks or end of intervention)</time_frame>
        <population>LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Active Repetitive Transcanial Magnetic Stimulation</title>
            <description>Participants received active repetitive transcranial magnetic stimulation (rTMS)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received sham stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hallucination Frequency After 9 Active/Shame rTMS Sessions</title>
          <description>Difference between baseline hallucination frequency and hallucintion frequency at last assessment. Assessed on the basis of a 0-9 scale, with higher scores being more severe.</description>
          <population>LOCF</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="1.49"/>
                    <measurement group_id="O2" value=".15" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>null hypothesis is that the groups are the same</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.002</p_value>
            <p_value_desc>a priori threshold for statistical significance was .05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>degrees of freedom = 48</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.327</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>.507</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Improvement (CGI) Scale After 9 Active/Shame rTMS Sessions</title>
        <description>Scaled from 1-7 as follows: 1=dramatically improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worsened, 6=moderately worsened, 7=dramatically worsened</description>
        <time_frame>After the 9th active/sham rTMS session (up to 2 weeks or end of intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Repetitive Transcanial Magnetic Stimulation</title>
            <description>Participants received active repetitive transcranial magnetic stimulation (rTMS)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received sham stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Improvement (CGI) Scale After 9 Active/Shame rTMS Sessions</title>
          <description>Scaled from 1-7 as follows: 1=dramatically improved, 2=moderately improved, 3=minimally improved, 4=no change, 5=minimally worsened, 6=moderately worsened, 7=dramatically worsened</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" spread=".845"/>
                    <measurement group_id="O2" value="3.79" spread=".882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.001</p_value>
            <p_value_desc>A priori threshold for statistical significance was .05</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>degrees of freedom = 46</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-.949</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>.524</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.45</ci_lower_limit>
            <ci_upper_limit>-.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Status</title>
        <description>Responder defined as a participant who attains an endpoint hallucination change score (HCS) of 5 or lower after 9 active/shame rTMS sessions.
Change in hallucination severity relative to baseline with scores ranging 1 in unit intervals to 20 anchored as follows: 0=hallucinations stopped, 10=no change, 20=hallucinations twice as severe as baseline</description>
        <time_frame>After the 9th active/sham rTMS session (up to 2 weeks or end of intervention)</time_frame>
        <population>LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Active Repetitive Transcanial Magnetic Stimulation</title>
            <description>Participants received active repetitive transcranial magnetic stimulation (rTMS)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received sham stimulation</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Status</title>
          <description>Responder defined as a participant who attains an endpoint hallucination change score (HCS) of 5 or lower after 9 active/shame rTMS sessions.
Change in hallucination severity relative to baseline with scores ranging 1 in unit intervals to 20 anchored as follows: 0=hallucinations stopped, 10=no change, 20=hallucinations twice as severe as baseline</description>
          <population>LOCF</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.01</p_value>
            <p_value_desc>a priori threshold for statistical significance = .05</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event reporting was collected for the duration of the study (41 months)</time_frame>
      <desc>Adverse events were systematically collected with focused questions each day during the trial</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Repetitive Transcanial Magnetic Stimulation</title>
          <description>Participants received active repetitive transcranial magnetic stimulation (rTMS)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received sham stimulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Transient headache and responsive to acetaminophen</description>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ralph Hoffman</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-688-9734</phone>
      <email>ralph.hoffman@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

